Progress in personalized nano-tumor vaccines
- Japan’s childhood hepatitis cases of unknown etiology rise to 31
- No need COVID-19 vaccination and quarantine when entering these countries
- New strategy for tumor immunotherapy: Lactate metabolism in Treg cells
- Global tumor new drug research and development report released
- Stem cells can reverse premature ovarian failure
- Can natural killer cells-NK cells also fight against COVID-19?
Progress in personalized nano-tumor vaccines
- Unexplained acute hepatitis in children may be related to COVID superantigens
- How long can the patient live after heart stent surgery?
- Keytruda: The 5-year survival rate for advanced lung cancer doubled!
- Amylyx released the latest statistical analysis of new ALS drugs after being opposed by FDA panel last month
- Celine Dion is paralyzed due to muscle cramps: What are Muscle Cramps?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
Progress in personalized nano-tumor vaccines.
Individualized tumor vaccines are very important in tumor immunotherapy. By presenting tumor antigens to the immune system, they stimulate the production of tumor antigen-specific killer T cells and inhibit tumor growth and metastasis.
However, how to efficiently present diverse tumor antigens to the immune system has become a key issue for tumor vaccines, and nanocarrier technology plays an important role in it.
Researcher Nie Guangjun and researcher Zhao Xiao of the China Nanoscience Center have made progress in the design of personalized nano-tumor vaccines.
The related research results are “Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display” “Technology”, published on Nature Communications.
Nie Guangjun’s research group and Zhao Xiao’s research group have long been committed to the use of nanotechnology to enhance tumor immunotherapy research: through the design of amphipathic peptides, two nanoinhibitors of immune checkpoints have been successfully developed (Nano. Lett. 2018, 18, 3250-3258; J. Am. Chem. Soc. 2020, 142, 5, 2490-2496); using genetic engineering technology, successfully constructed a chimeric natural nanovesicle OMV-PD1 (ACS Nano 2020, 14, 12, 16698-16711); based on the principle of click chemistry, a tumor vaccine with artificial lymph node targeting properties was constructed (DOI: 10.1002/adma.202006007).
Based on the previous work, researchers used genetic engineering technology and peptide molecular glue technology to build a personalized tumor vaccine platform based on natural nanocarriers-bacterial outer membrane vesicles (OMV) (pictured) .
Researchers use genetic engineering technology to fusion and express one end of the peptide molecule glue on the surface of OMV, and the other end is used as a label to connect with tumor antigens. After the two are mixed, rapid covalent connection can occur, thereby achieving rapid tumor antigens on OMV. Flexible display.
As a vaccine carrier, OMV can rely on its size advantage to achieve efficient drainage of lymph nodes, and has the immune adjuvant function to activate a variety of natural immune pathways, and ultimately display a strong anti-tumor immune response in a variety of preclinical tumor models.
In summary, the research has established a “plug and play” OMV tumor vaccine platform, which can quickly display tumor antigens and achieve efficient delivery and immune stimulation, which can better meet the clinical needs of complex and variable tumor antigens, and promote individuals Development of chemical tumor vaccines
Progress in personalized nano-tumor vaccines
(source:internet, reference only)
Disclaimer of medicaltrend.org
